Guido Magni
Partner @ Versant Ventures
Basel, Switzerland
Guido Magni is a Series A investor at Versant Ventures in Basel focused on Biotechnology and Medical. Guido Magni is based out of Basel, Basel-Stadt, and is the partner of Versant Ventures. Guido previously worked at Roche Pharmaceuticals as a head of medical science WW, global drug development. Guido Magni attended the Università degli Studi di Padova.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Guido Magni invests in
Stages Guido Magni invests in
Countries Guido Magni invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (57%)
- Medical 3 (43%)
- Health Care 3 (43%)
- Genetics 2 (29%)
- Life Science 1 (14%)
Stage
- Series A 3 (43%)
- Series B 2 (29%)
- Series C 2 (29%)
Country
- France 1 (14%)
- Sweden 1 (14%)
- Switzerland 1 (14%)
- The Netherlands 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized for the efficient expression of long strings of tumor neoantigens. It also includes a toolkit for inducing broad andpotent antitumor T-cell responses, allowing patients to boost cancer-specific cellular immunity. | $73.4M / Series C / Nov 14, 2023 | ||
| Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals thatarm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors. | $83M / Series C / Sep 17, 2020 | ||
| Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals thatarm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors. | $18.7M / Series A / May 23, 2018 | ||
| Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized for the efficient expression of long strings of tumor neoantigens. It also includes a toolkit for inducing broad andpotent antitumor T-cell responses, allowing patients to boost cancer-specific cellular immunity. | $48.8M / Series B / Nov 06, 2017 | ||
| Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized for the efficient expression of long strings of tumor neoantigens. It also includes a toolkit for inducing broad andpotent antitumor T-cell responses, allowing patients to boost cancer-specific cellular immunity. | $13.6M / Series A / May 17, 2016 | ||
| Aprea is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicleowned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB. | $50.6M / Series B / Mar 09, 2016 | ||
| GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $35.1M / Series A / Apr 08, 2013 |
Co-Investors
About Versant Ventures
Versant Ventures is a healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and officesin Canada, the U.S., and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.
Versant Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Clare Ozawa
Managing Director
|
|||
Donald Milder
Managing Director
|
|||
Gianni Gromo
Partner
|
|||
|
Guido Magni
Partner
|
|||
Max Eisenberg
General Counsel
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Guido Magni invest in?
Guido Magni invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Guido Magni?
Public channels for Guido Magni include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Guido Magni last invest?
The most recent investment recorded for Guido Magni closed in Nov 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
